Treatment of Catheter-Detected Occlusion Due to Clot

Coronary Artery Occlusion

The American Heart Association recommends mechanical restoration of coronary blood flow through immediate coronary angioplasty or stent placement as the definitive treatment for coronary artery thrombosis in patients large enough for adult catheters 1
The European Society of Cardiology suggests that thrombus aspiration catheter devices should be used to remove clot burden before or during PCI 3, 4
Procedures should be performed by or with assistance of experienced interventional cardiologists to reestablish perfusion as quickly as possible 1
The American College of Cardiology recommends administering aspirin and a P2Y12 inhibitor (ticagrelor or prasugrel preferred over clopidogrel in acute settings) immediately 3, 4
Glycoprotein IIb/IIIa inhibitor (abciximab 0.25 mg/kg bolus over 30 minutes, followed by 0.125 μg·kg⁻¹·min⁻¹ for 12 hours) should be considered for large thrombus burden 1, 5
Systemic anticoagulation with heparin must be initiated immediately 5, 6
Thrombolytic therapy (alteplase, reteplase, or urokinase) is indicated for coronary artery thrombosis with actual or impending occlusion when mechanical intervention cannot be performed expeditiously 1

The American Heart Association recommends catheter-directed thrombolysis as the preferred initial treatment for acute limb ischemia (Rutherford categories I and IIa) of less than 14 days' duration 2
Immediate anticoagulation with heparin should be started before any intervention 5, 6
Mechanical thrombectomy devices can be used as adjunctive therapy 2
Native-vessel thrombosis: Trial of catheter-directed thrombolysis for viable limbs when guidewire can be passed across the lesion 5, 6
Embolic occlusions: Isolated suprainguinal emboli should be removed surgically; distal embolization requires catheter-directed thrombolytic therapy 5
Occluded bypass grafts: Catheter-directed thrombolysis is preferred for grafts occluded <14 days 5

Alteplase (Cathflo Activase) is the agent of choice for catheter occlusion: 2 mg in 2 mL for patients ≥30 kg; 110% of internal lumen volume (not exceeding 2 mg in 2 mL) for patients <30 kg 9
Reteplase may achieve similar efficacy with shorter dwell times (mean 38 minutes) 9
Recombinant urokinase clears 60% of catheters at 30 minutes with 73% overall clearance 9

Low molecular weight heparin (LMWH) subcutaneously or unfractionated heparin intravenously is the main initial therapy for catheter-related venous thrombosis 9, 10
Continue anticoagulation for minimum 3 months at therapeutic doses 9, 10
After 3 months, switch to prophylactic doses until catheter removal 9, 10
When catheter is no longer necessary or long-term anticoagulation is contraindicated, administer 3-5 days of anticoagulation before removal to prevent clot embolization 10
If symptoms progress or clot extends into superior vena cava, remove the catheter 10

Never delay anticoagulation while awaiting imaging if clinical suspicion is high and no contraindications exist 11
Do not discontinue both antiplatelet agents simultaneously in patients with recent coronary stent placement, as this dramatically increases stent thrombosis risk 3, 4
Thrombolytic treatment is not recommended as first-line therapy for catheter-related thrombosis due to greater bleeding risk compared to anticoagulation alone 10